Psoriatic arthritis and chronic lymphoedema: treatment efficacy by adalimumab.

Abstract

Lymphoedema is a rare complication of psoriatic arthritis (PsA) and inflammatory joint disease, with no response noted to disease-modifying drugs. However, reports are emerging of a beneficial effect on lymphoedema in patients treated with tumor necrosis factor-alpha antagonists for PsA (Etanercept), rheumatoid arthritis (Etanercept) and ankylosing spondylitis (Infliximab). We describe a psoriatic arthritis patient whose lymphoedema greatly improved following commencement of adalimumab.

• Authors: Denise Tong, Sharron Eather, Nicholas Manolios
• Journal: Clinical rheumatology (Clin Rheumatol) Vol. 28 Issue 11 Pg. 1349-50 (Nov 2009) ISSN: 1434-9949 [Electronic] Germany
• PMID: 19693641 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Tumor Necrosis Factor-alpha
• Adalimumab

Topics

• Adalimumab
• Anti-Inflammatory Agents (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Arthritis, Psoriatic (complications, drug therapy, pathology)
• Humans
• Lymphedema (complications, drug therapy, pathology)
• Male
• Middle Aged
• Treatment Outcome
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)